4.7 Article

Metformin Affects Cardiac Arachidonic Acid Metabolism and Cardiac Lipid Metabolite Storage in a Prediabetic Rat Model

Journal

Publisher

MDPI
DOI: 10.3390/ijms22147680

Keywords

metformin; stearoyl-CoA desaturase; fatty acid profile; myocardial phospholipids; arachidonic acid; cytochrome P450; myocardial function; lipotoxic intermediates

Funding

  1. Ministry of Health of the Czech Republic under its conceptual development of research organizations program (Institute for Clinical and Experimental Medicine-IKEM [IN 00023001]
  2. [IGA_LF_2021_013]

Ask authors/readers for more resources

Metformin can reduce cardiovascular risk independently of glycemic control, with non-glycemic benefits such as improved lipid and fatty acid metabolism and lower blood pressure. In a rat model, metformin treatment reduced accumulation of neutral lipids in the myocardium and showed associations with gene expression and enzyme activity. Additionally, metformin improved fatty acid composition in the heart muscle and had positive effects on arachidonic acid metabolism and related metabolites.
Metformin can reduce cardiovascular risk independent of glycemic control. The mechanisms behind its non-glycemic benefits, which include decreased energy intake, lower blood pressure and improved lipid and fatty acid metabolism, are not fully understood. In our study, metformin treatment reduced myocardial accumulation of neutral lipids-triglycerides, cholesteryl esters and the lipotoxic intermediates-diacylglycerols and lysophosphatidylcholines in a prediabetic rat model (p < 0.001). We observed an association between decreased gene expression and SCD-1 activity (p < 0.05). In addition, metformin markedly improved phospholipid fatty acid composition in the myocardium, represented by decreased SFA profiles and increased n3-PUFA profiles. Known for its cardioprotective and anti-inflammatory properties, metformin also had positive effects on arachidonic acid metabolism and CYP-derived arachidonic acid metabolites. We also found an association between increased gene expression of the cardiac isoform CYP2c with increased 14,15-EET (p < 0.05) and markedly reduced 20-HETE (p < 0.001) in the myocardium. Based on these results, we conclude that metformin treatment reduces the lipogenic enzyme SCD-1 and the accumulation of the lipotoxic intermediates diacylglycerols and lysophosphatidylcholine. Increased CYP2c gene expression and beneficial effects on CYP-derived arachidonic acid metabolites in the myocardium can also be involved in cardioprotective effect of metformin.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available